175 related articles for article (PubMed ID: 9337351)
1. Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance.
de las Alas MM; Aebi S; Fink D; Howell SB; Los G
J Natl Cancer Inst; 1997 Oct; 89(20):1537-41. PubMed ID: 9337351
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy-induced O(6)-benzylguanine-resistant alkyltransferase mutations in mismatch-deficient colon cancer.
Liu L; Schwartz S; Davis BM; Gerson SL
Cancer Res; 2002 Jun; 62(11):3070-6. PubMed ID: 12036916
[TBL] [Abstract][Full Text] [Related]
3. Antisense inhibition of hMLH1 is not sufficient for loss of DNA mismatch repair function in the HCT116+chromosome 3 cell line.
Chauhan DP; Yang Q; Carethers JM; Marra G; Chang CL; Chamberlain SM; Boland CR
Clin Cancer Res; 2000 Oct; 6(10):3827-31. PubMed ID: 11051225
[TBL] [Abstract][Full Text] [Related]
4. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins.
Sergent C; Franco N; Chapusot C; Lizard-Nacol S; Isambert N; Correia M; Chauffert B
Cancer Chemother Pharmacol; 2002 Jun; 49(6):445-52. PubMed ID: 12107548
[TBL] [Abstract][Full Text] [Related]
5. P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin.
Lin X; Ramamurthi K; Mishima M; Kondo A; Christen RD; Howell SB
Cancer Res; 2001 Feb; 61(4):1508-16. PubMed ID: 11245458
[TBL] [Abstract][Full Text] [Related]
6. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells.
Aebi S; Fink D; Gordon R; Kim HK; Zheng H; Fink JL; Howell SB
Clin Cancer Res; 1997 Oct; 3(10):1763-7. PubMed ID: 9815561
[TBL] [Abstract][Full Text] [Related]
7. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses.
Meyers M; Wagner MW; Hwang HS; Kinsella TJ; Boothman DA
Cancer Res; 2001 Jul; 61(13):5193-201. PubMed ID: 11431359
[TBL] [Abstract][Full Text] [Related]
8. Effect of H(2)O(2) on cell cycle and survival in DNA mismatch repair-deficient and -proficient cell lines.
Chang DK; Goel A; Ricciardiello L; Lee DH; Chang CL; Carethers JM; Boland CR
Cancer Lett; 2003 Jun; 195(2):243-51. PubMed ID: 12767533
[TBL] [Abstract][Full Text] [Related]
9. The mismatch repair protein, hMLH1, mediates 5-substituted halogenated thymidine analogue cytotoxicity, DNA incorporation, and radiosensitization in human colon cancer cells.
Berry SE; Garces C; Hwang HS; Kunugi K; Meyers M; Davis TW; Boothman DA; Kinsella TJ
Cancer Res; 1999 Apr; 59(8):1840-5. PubMed ID: 10213489
[TBL] [Abstract][Full Text] [Related]
10. Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter.
Plumb JA; Strathdee G; Sludden J; Kaye SB; Brown R
Cancer Res; 2000 Nov; 60(21):6039-44. PubMed ID: 11085525
[TBL] [Abstract][Full Text] [Related]
11. Mutation rate at the hprt locus in human cancer cell lines with specific mismatch repair-gene defects.
Glaab WE; Tindall KR
Carcinogenesis; 1997 Jan; 18(1):1-8. PubMed ID: 9054582
[TBL] [Abstract][Full Text] [Related]
12. Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines.
Arnold CN; Goel A; Boland CR
Int J Cancer; 2003 Aug; 106(1):66-73. PubMed ID: 12794758
[TBL] [Abstract][Full Text] [Related]
13. Expression of DNA repair proteins hMSH2, hMSH6, hMLH1, O6-methylguanine-DNA methyltransferase and N-methylpurine-DNA glycosylase in melanoma cells with acquired drug resistance.
Lage H; Christmann M; Kern MA; Dietel M; Pick M; Kaina B; Schadendorf D
Int J Cancer; 1999 Mar; 80(5):744-50. PubMed ID: 10048977
[TBL] [Abstract][Full Text] [Related]
14. Detection of an involvement of the human mismatch repair genes hMLH1 and hMSH2 in nucleotide excision repair is dependent on UVC fluence to cells.
Lee DF; Drouin R; Pitsikas P; Rainbow AJ
Cancer Res; 2004 Jun; 64(11):3865-70. PubMed ID: 15172995
[TBL] [Abstract][Full Text] [Related]
15. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells.
Jacob S; Aguado M; Fallik D; Praz F
Cancer Res; 2001 Sep; 61(17):6555-62. PubMed ID: 11522654
[TBL] [Abstract][Full Text] [Related]
16. Resistance to 6-thioguanine in mismatch repair-deficient human cancer cell lines correlates with an increase in induced mutations at the HPRT locus.
Glaab WE; Risinger JI; Umar A; Barrett JC; Kunkel TA; Tindall KR
Carcinogenesis; 1998 Nov; 19(11):1931-7. PubMed ID: 9855005
[TBL] [Abstract][Full Text] [Related]
17. Loss of DNA mismatch repair in acquired resistance to cisplatin.
Aebi S; Kurdi-Haidar B; Gordon R; Cenni B; Zheng H; Fink D; Christen RD; Boland CR; Koi M; Fishel R; Howell SB
Cancer Res; 1996 Jul; 56(13):3087-90. PubMed ID: 8674066
[TBL] [Abstract][Full Text] [Related]
18. The role of DNA mismatch repair in platinum drug resistance.
Fink D; Nebel S; Aebi S; Zheng H; Cenni B; Nehmé A; Christen RD; Howell SB
Cancer Res; 1996 Nov; 56(21):4881-6. PubMed ID: 8895738
[TBL] [Abstract][Full Text] [Related]
19. Hypersensitivity in DNA mismatch repair-deficient colon carcinoma cells to DNA polymerase reaction inhibitors.
Takahashi T; Min Z; Uchida I; Arita M; Watanabe Y; Koi M; Hemmi H
Cancer Lett; 2005 Mar; 220(1):85-93. PubMed ID: 15737691
[TBL] [Abstract][Full Text] [Related]
20. Human cells bearing homozygous mutations in the DNA mismatch repair genes hMLH1 or hMSH2 are fully proficient in transcription-coupled nucleotide excision repair.
Rochette PJ; Bastien N; McKay BC; Therrien JP; Drobetsky EA; Drouin R
Oncogene; 2002 Aug; 21(37):5743-52. PubMed ID: 12173044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
